EE201200003A - Fulvestrant 500 mg suuruse annusena kaugelearenenud rinnav„hi raviks - Google Patents

Fulvestrant 500 mg suuruse annusena kaugelearenenud rinnav„hi raviks

Info

Publication number
EE201200003A
EE201200003A EEP201200003A EEP201200003A EE201200003A EE 201200003 A EE201200003 A EE 201200003A EE P201200003 A EEP201200003 A EE P201200003A EE P201200003 A EEP201200003 A EE P201200003A EE 201200003 A EE201200003 A EE 201200003A
Authority
EE
Estonia
Prior art keywords
fulvestrant
dose
treatment
advanced breast
breast
Prior art date
Application number
EEP201200003A
Other languages
English (en)
Estonian (et)
Inventor
William Dimery Isaiah
Webster Alan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41066853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE201200003(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE201200003A publication Critical patent/EE201200003A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
EEP201200003A 2009-07-27 2010-07-26 Fulvestrant 500 mg suuruse annusena kaugelearenenud rinnav„hi raviks EE201200003A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0912999.0A GB0912999D0 (en) 2009-07-27 2009-07-27 Method-803
PCT/GB2010/051228 WO2011012885A1 (en) 2009-07-27 2010-07-26 Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer

Publications (1)

Publication Number Publication Date
EE201200003A true EE201200003A (et) 2012-04-16

Family

ID=41066853

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP201200003A EE201200003A (et) 2009-07-27 2010-07-26 Fulvestrant 500 mg suuruse annusena kaugelearenenud rinnav„hi raviks

Country Status (36)

Country Link
US (1) US20120214778A1 (enExample)
EP (1) EP2459199A1 (enExample)
JP (1) JP2013500324A (enExample)
KR (1) KR20120042843A (enExample)
AT (1) AT510868A2 (enExample)
AU (1) AU2010277373A1 (enExample)
BG (1) BG111123A (enExample)
BR (1) BR112012001837A2 (enExample)
CA (1) CA2768286A1 (enExample)
CL (1) CL2012000226A1 (enExample)
CZ (1) CZ201235A3 (enExample)
DE (1) DE112010003084T5 (enExample)
DK (1) DK201270089A (enExample)
EA (1) EA201200190A1 (enExample)
EC (1) ECSP12011629A (enExample)
EE (1) EE201200003A (enExample)
ES (1) ES2393323A1 (enExample)
FI (1) FI20125207L (enExample)
GB (2) GB0912999D0 (enExample)
HR (1) HRP20120084A2 (enExample)
HU (1) HUP1200203A3 (enExample)
IL (1) IL217527A0 (enExample)
IS (1) IS8994A (enExample)
LT (1) LT5953B (enExample)
MX (1) MX2012001282A (enExample)
NO (1) NO20120147A1 (enExample)
PE (1) PE20121177A1 (enExample)
PL (1) PL399129A1 (enExample)
RO (1) RO128705A2 (enExample)
RS (1) RS20120022A1 (enExample)
SE (1) SE1250155A1 (enExample)
SG (1) SG177586A1 (enExample)
SK (1) SK500052012A3 (enExample)
TR (1) TR201200950T1 (enExample)
WO (1) WO2011012885A1 (enExample)
ZA (1) ZA201201406B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
RU2016148441A (ru) * 2014-05-21 2018-06-22 Ф. Хоффманн-Ля Рош Аг Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом
WO2017201189A1 (en) * 2016-05-17 2017-11-23 Abraxis Bioscience, Llc Methods for assessing neoadjuvant therapies
MX386903B (es) * 2016-10-21 2025-03-19 Crescita Therapeutics Inc Composiciones farmacéuticas tópicas y uso en el tratamiento de afecciones cutáneas.
US20180153868A1 (en) * 2016-12-06 2018-06-07 Gilead Sciences, Inc. Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent
KR102267378B1 (ko) * 2019-09-10 2021-06-21 가천대학교 산학협력단 C12, c16 또는 c18-세라마이드를 유효성분으로 함유하는 유방암 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
GB201201486D0 (en) 2012-03-14
PE20121177A1 (es) 2012-09-23
FI20125207A7 (fi) 2012-02-23
LT5953B (lt) 2013-07-25
US20120214778A1 (en) 2012-08-23
RO128705A2 (ro) 2013-08-30
KR20120042843A (ko) 2012-05-03
MX2012001282A (es) 2012-06-12
CL2012000226A1 (es) 2012-08-31
EP2459199A1 (en) 2012-06-06
GB0912999D0 (en) 2009-09-02
LT2012006A (lt) 2013-03-25
ECSP12011629A (es) 2012-02-29
SK500052012A3 (sk) 2012-04-03
IS8994A (is) 2012-02-24
ES2393323A1 (es) 2012-12-20
GB2484050A (en) 2012-03-28
NO20120147A1 (no) 2012-04-03
BR112012001837A2 (pt) 2016-03-15
WO2011012885A9 (en) 2011-03-24
DE112010003084T5 (de) 2012-09-06
PL399129A1 (pl) 2012-11-19
HUP1200203A1 (en) 2012-09-28
EA201200190A1 (ru) 2012-08-30
AT510868A2 (de) 2012-07-15
BG111123A (bg) 2012-10-31
SG177586A1 (en) 2012-02-28
RS20120022A1 (sr) 2012-10-31
DK201270089A (en) 2012-02-24
CA2768286A1 (en) 2011-02-03
FI20125207L (fi) 2012-02-23
HUP1200203A3 (en) 2012-12-28
WO2011012885A1 (en) 2011-02-03
JP2013500324A (ja) 2013-01-07
HRP20120084A2 (hr) 2012-04-30
AU2010277373A1 (en) 2012-02-09
SE1250155A1 (sv) 2012-02-22
TR201200950T1 (tr) 2012-09-21
ZA201201406B (en) 2013-08-28
CZ201235A3 (cs) 2012-06-27
IL217527A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
IL259475A (en) Combined therapy for the treatment of diabetes
HUE047994T2 (hu) Bardoxolon-metil elhízás kezelésére
HUE039731T2 (hu) l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére
HUE038042T2 (hu) PPAR helyettesítõ tiazolidindion sók metabolikus betegségek kezelésére
ZA201006752B (en) Spiro-indole derivatives for the treatment of parasitic disease
GB0904287D0 (en) Compounds for the treatment of metabolic disorders
GB0904285D0 (en) Compounds for the treatment of metabolic disorders
IL225371A0 (en) Focoxim conjugates are useful for the treatment of pathologies related to 90hsp
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
ZA201107445B (en) Compound for the treatment of metabolic disorders
FI20125207L (fi) Fulvestrantti 500 mg annoksena pitkälle edenneen rintasyövän hoitoon
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
PT2424870E (pt) Agentes terapêuticos 713
DK2421858T3 (en) Thioxanthene derivatives for the treatment of infectious diseases
GB0904286D0 (en) Compounds for the treatment of metabolic disorders
GB0904290D0 (en) Compounds for the treatment of metabolic disorders
GB0904288D0 (en) Compounds for the treatment of metabolic disorders
GB0904289D0 (en) Compounds for the treatment of metabolic disorders
GB201009094D0 (en) Compounds for the treatment of closridium difficile-associated disease
GB201006454D0 (en) Functional sock for the treatment of plantar fasciitis